{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:07:48Z","timestamp":1792814868550,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial virus (RSV) disease with acceptable safety in adults aged \u226560 years in the ConquerRSV trial. Here, humoral immunogenicity results from the trial are presented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase 2\/3 trial randomly assigned adults (\u226560 years) to mRNA-1345 50-\u00b5g encoding prefusion F (preF) glycoprotein (n = 17 793) vaccine or placebo (n = 17 748). RSV-A and RSV-B neutralizing antibody (nAb) and preF binding antibody (bAb) levels at baseline and day 29 postvaccination were assessed in a per-protocol immunogenicity subset (PPIS; mRNA-1345, n = 1515; placebo, n = 333).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Day 29 nAb geometric mean titers (GMTs) increased 8.4-fold against RSV-A and 5.1-fold against RSV-B from baseline. Seroresponses (4-fold rise from baseline) in the mRNA-1345 groups were 74.2% and 56.5% for RSV-A and RSV-B, respectively. Baseline GMTs were lower among participants who met the seroresponse criteria than those who did not. mRNA-1345 induced preF bAbs at day 29, with a pattern similar to nAbs. Day 29 antibody responses across demographic and risk subgroups were generally consistent with the overall PPIS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>mRNA-1345 enhanced RSV-A and RSV-B nAbs and preF bAbs in adults (\u226560 years) across various subgroups, including those at risk for severe disease, consistent with its demonstrated efficacy in the prevention of RSV disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT05127434.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae316","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:15:04Z","timestamp":1718734504000},"page":"e996-e1006","source":"Crossref","is-referenced-by-count":47,"title":["Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults"],"prefix":"10.1093","volume":"230","author":[{"given":"Jaya","family":"Goswami","sequence":"first","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah H","family":"Baqui","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A","family":"Doreski","sequence":"additional","affiliation":[{"name":"Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Perez Marc","sequence":"additional","affiliation":[{"name":"Consultorios M\u00e9dicos Dr. Doreski , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Spotlight Research Center , Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salahuddin","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins University , Zakiganj, Sylhet, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalequz","family":"Zaman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Matlab Health Research Center , Matlab Bazar ,","place":["Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J A","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Victoria Infirmary , Newcastle upon Tyne, Northumberland ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8150-075X","authenticated-orcid":false,"given":"Mugen","family":"Ujiie","sequence":"additional","affiliation":[{"name":"Center for Global Health and Medicine , Shinjuku-Ku ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"R\u00e4met","sequence":"additional","affiliation":[{"name":"Finnish Vaccine Research Ltd"},{"name":"Faculty of Medicine and Health Technology, Tampere University , Tampere ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"P\u00e9rez\u2013Breva","sequence":"additional","affiliation":[{"name":"Vaccine Research, FISABIO\u2013Public Health , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejun","family":"Du","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddah","family":"Mehta","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E","family":"Tomassini","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmei","family":"Huang","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia K","family":"Stoszek","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Lin","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Le Cam","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A","family":"Shaw","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Slobod","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Wilson","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M","family":"Miller","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc. , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"2024111514560352700_jiae316-B1","article-title":"RSV in older adults and adults with chronic medical conditions","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2024111514560352700_jiae316-B2","doi-asserted-by":"crossref","first-page":"220105","DOI":"10.1183\/16000617.0105-2022","article-title":"Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries","volume":"31","author":"Nguyen-Van-Tam","year":"2022","journal-title":"Eur Respir Rev"},{"key":"2024111514560352700_jiae316-B3","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"2024111514560352700_jiae316-B4","doi-asserted-by":"crossref","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999\u20132018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024111514560352700_jiae316-B5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/CVI.00580-12","article-title":"Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein","volume":"20","author":"Cherukuri","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"2024111514560352700_jiae316-B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024111514560352700_jiae316-B7","doi-asserted-by":"crossref","first-page":"2002688","DOI":"10.1183\/13993003.02688-2020","article-title":"Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study","volume":"57","author":"Korsten","year":"2021","journal-title":"Eur Respir J"},{"key":"2024111514560352700_jiae316-B8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2024111514560352700_jiae316-B9","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global disease burden estimates of respiratory syncytial virus\u2013associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J Infect Dis"},{"key":"2024111514560352700_jiae316-B10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2024111514560352700_jiae316-B11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines9060624","article-title":"Considerations for a respiratory syncytial virus vaccine targeting an elderly population","volume":"9","author":"Stephens","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2024111514560352700_jiae316-B12","doi-asserted-by":"crossref","first-page":"eadg6050","DOI":"10.1126\/scitranslmed.adg6050","article-title":"The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains","volume":"15","author":"Sacconnay","year":"2023","journal-title":"Sci Transl Med"},{"key":"2024111514560352700_jiae316-B13","doi-asserted-by":"crossref","first-page":"e4421","DOI":"10.1093\/cid\/ciaa648","article-title":"Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life","volume":"73","author":"Buchwald","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024111514560352700_jiae316-B14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O\u2019Brien","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2024111514560352700_jiae316-B15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"key":"2024111514560352700_jiae316-B16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/380907","article-title":"Risk factors for severe respiratory syncytial virus infection in elderly persons","volume":"189","author":"Walsh","year":"2004","journal-title":"J Infect Dis"},{"key":"2024111514560352700_jiae316-B17","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S2666-7568(22)00103-9","article-title":"Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model","volume":"3","author":"Ascough","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"2024111514560352700_jiae316-B18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1086\/429695","article-title":"Respiratory syncytial virus\u2013specific CD8+ memory T cell responses in elderly persons","volume":"191","author":"de Bree","year":"2005","journal-title":"J Infect Dis"},{"key":"2024111514560352700_jiae316-B19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"2024111514560352700_jiae316-B20","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F\u2013specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"2024111514560352700_jiae316-B21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu Rev Med"},{"key":"2024111514560352700_jiae316-B22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2024111514560352700_jiae316-B23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"2024111514560352700_jiae316-B24","article-title":"U.S. FDA approves ABRYSVO, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults","author":"Pfizer","year":"2023"},{"key":"2024111514560352700_jiae316-B25","author":"European Medicines Agency","year":"2023"},{"key":"2024111514560352700_jiae316-B26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"2024111514560352700_jiae316-B27","article-title":"FDA approves first respiratory syncytial virus (RSV) vaccine","author":"US Food and Drug Administration","year":"2023"},{"key":"2024111514560352700_jiae316-B28","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"2024111514560352700_jiae316-B29","doi-asserted-by":"crossref","first-page":"ofac492.312","DOI":"10.1093\/ofid\/ofac492.312","article-title":"Safety and immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: results from a phase 1, randomized clinical trial","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024111514560352700_jiae316-B30","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1093\/infdis\/jiae081","article-title":"Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults","volume":"230","author":"Shaw","year":"2024","journal-title":"J Infect Dis"},{"key":"2024111514560352700_jiae316-B31","article-title":"Efficacy and safety of mRNA-1345, an RSV vaccine, in older adults: results through \u22656 months of follow-up","author":"Wilson","year":"2024"},{"key":"2024111514560352700_jiae316-B32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ageing\/afl041","article-title":"Validity and reliability of the Edmonton Frail Scale","volume":"35","author":"Rolfson","year":"2006","journal-title":"Age Ageing"},{"key":"2024111514560352700_jiae316-B33","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus\u2014Zaire Ebola virus envelope glycoprotein vaccine: an evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"key":"2024111514560352700_jiae316-B34","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.vaccine.2013.03.065","article-title":"Evaluation of vaccine-induced antibody responses: impact of new technologies","volume":"31","author":"Zaccaro","year":"2013","journal-title":"Vaccine"},{"key":"2024111514560352700_jiae316-B35","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1016\/j.vaccine.2007.04.042","article-title":"A new approach to the definition of seroconversion following vaccination in a population with high background antibody concentrations","volume":"25","author":"Chandramohan","year":"2007","journal-title":"Vaccine"},{"key":"2024111514560352700_jiae316-B36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024111514560352700_jiae316-B37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-422X-11-36","article-title":"Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in southern Brazil","volume":"11","author":"de-Paris","year":"2014","journal-title":"Virol J"},{"key":"2024111514560352700_jiae316-B38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13052-019-0704-0","article-title":"Respiratory syncytial virus A and B: three bronchiolitis seasons in a third level hospital in Italy","volume":"45","author":"Ciarlitto","year":"2019","journal-title":"Ital J Pediatr"},{"key":"2024111514560352700_jiae316-B39","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"2024111514560352700_jiae316-B40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/vaccines11030672","article-title":"RSV A2-based prefusion F vaccine candidates induce RSV A and RSV B cross binding and neutralizing antibodies and provide protection against RSV A and RSV B challenge in preclinical models","volume":"11","author":"Cox","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2024111514560352700_jiae316-B41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr Opin Virol"},{"key":"2024111514560352700_jiae316-B42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2019.03.005","article-title":"Immunological goals for respiratory syncytial virus vaccine development","volume":"59","author":"Graham","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"2024111514560352700_jiae316-B43","volume-title":"Safety and immunogenicity of mRNA-1345, an mRNA-based vaccine against RSV in older adults through 6 month follow-up.","author":"Stoszek"},{"key":"2024111514560352700_jiae316-B44","volume-title":"T-cell responses following vaccination with an mRNA respiratory syncytial virus vaccine, mRNA-1345, in older adults","author":"Paris"},{"key":"2024111514560352700_jiae316-B45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1\/2 randomized clinical trial","volume":"227","author":"Leroux-Roels","year":"2022","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae316\/58500765\/jiae316.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/5\/e996\/60683879\/jiae316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/5\/e996\/60683879\/jiae316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T14:56:24Z","timestamp":1731682584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/5\/e996\/7695859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,18]]},"published-print":{"date-parts":[[2024,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae316","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,15]]},"published":{"date-parts":[[2024,6,18]]}}}